Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

SMT Supraflex Cruz Stent Approved in Canada

Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval enables SMT to sell its coronary stent in Canada, potentially increasing revenue and market share in North America. As SMT is pre-IPO, this regulatory milestone may positively influence investor sentiment ahead of its planned public offering.

Medical Devices

Sahajanand Medical Technologies Limited (SMT) received a Class IV medical device license from Canada — Health Canada's Medical Devices Directorate for its Supraflex Cruz sirolimus-eluting coronary stent system. This approval allows the device to be imported and sold in Canada, marking SMT's entry into the Canadian market. The license covers the Supraflex Sirolimus Eluting Stent System family and lists Supraflex Cruz as a licensed device. This approval is part of SMT's strategy to expand international availability of its coronary-intervention technologies. The company is also preparing for an initial public offering in India, having filed a draft red herring prospectus with SEBI.

priv
Received regulatory approval from Canada — Health Canada for its Supraflex Cruz stent, expanding market access and supporting its pre-IPO growth narrative.
Importance 100.0 Sentiment 60.0
govactor
Granted the Class IV medical device license, acting as the regulatory authority enabling SMT's market entry.
Importance 80.0 Sentiment 0.0
cnt
Serves as the new market where the stent is now approved for sale, with heart disease being a significant health burden.
Importance 50.0 Sentiment 0.0
per
As Chief Commercial Officer, commented on the approval, representing SMT's commercial leadership.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.